調査レポートカテゴリー： MarketsandMarkets, 世界

Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023

PoC分子診断の世界市場予測（～2023年）

◆タイトル：Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023
◆商品コード：MD6292
◆調査・発行会社：MarketsandMarkets
◆発行日：2018年5月17日
◆ページ数：108
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル、世界主要地域・国
◆産業分野：Medical Devices
◆販売価格オプション（消費税別）
Single User（1名利用）USD5,650 ⇒換算￥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥896,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、PoC分子診断の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品・サービス（アッセイ、キット、分析装置、ソフトウェア）別分析、用途別分析、技術別分析、需要先別分析、PoC分子診断の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The global POC molecular diagnostics market is projected to grow at a CAGR of 14.7%.”The global point of care (POC) molecular diagnostics market is expected to reach USD 1440.2 million by 2023 from USD 725.5 million in 2018, at a CAGR of 14.7%. Growth in the POC molecular diagnostics market is driven by the increasing prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests. However, inadequate reimbursement and stringent regulatory policies are likely to restrain the growth of this market during the forecast period.

“The INAAT technology is expected to grow at highest CAGR during the forecast period.”
Based on technology, the POC molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. The INAAT segment is expected to grow at highest CAGR during the forecasted period. The increasing popularity of INAAT for infectious diseases diagnosis is expected to drive this market in the coming years.
“Asia Pacific is projected to grow at the highest CAGR during the forecast period.”
While North America is expected to account for the largest share of the global POC molecular diagnostics market, Asia Pacific is projected to grow at the highest CAGR during the study period. The key factors influencing the growth of this market include growing initiatives by market players, rising demand for influenza A/B tests, decentralized healthcare delivery systems, and increasing patient population base in this region.
Break-up profile of primaries:

• By Company Type- Tier 40%, Tier 30%, and Tier 30%
• By Designation-C-level-27%, D-level-18%, and Others-55%
• By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global POC molecular diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Danaher (US), Biomerieux (France), and Meridian Biosciences (US)
Research Coverage:
The POC molecular diagnostics market in this report is segmented by product & service, application, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisition, collaborations, agreements, partnerships, and expansion, and profiles key players and their core competencies in the POC molecular diagnostics market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global POC molecular diagnostics market. The report analyzes the market by product & service, application type, technology, end user, and region
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global POC molecular diagnostics market
Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for POC molecular diagnostic products across regions
Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global POC molecular diagnostics market
Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global POC molecular diagnostics market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 12
1.2.1 MARKETS COVERED 12
1.2.2 YEARS CONSIDERED FOR THE STUDY 13
1.3 CURRENCY 13
1.4 LIMITATIONS 13
1.5 STAKEHOLDERS 13
2 RESEARCH METHODOLOGY 14
2.1 PRIMARY DATA 15
2.1.1 KEY DATA FROM PRIMARY SOURCES 15
2.1.2 KEY INDUSTRY INSIGHTS 16
2.2 SECONDARY DATA 17
2.2.1 KEY DATA FROM SECONDARY SOURCES 17
2.3 MARKET SIZE ESTIMATION 18
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.4.1 ASSUMPTIONS FOR THE STUDY 21
3 EXECUTIVE SUMMARY 22
4 PREMIUM INSIGHTS 25
4.1 POC MOLECULAR DIAGNOSTICS MARKET OVERVIEW 25
4.2 GEOGRAPHIC ANALYSIS: APAC POC MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY AND PRODUCT 26
4.3 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 27
4.4 POC MOLECULAR DIAGNOSTICS MARKET, BY END USER 27
5 MARKET OVERVIEW 28
5.1 INTRODUCTION 28
5.2 MARKET DYNAMICS 28
5.2.1 DRIVERS 29
5.2.1.1 Increasing worldwide prevalence of infectious diseases 29
5.2.1.2 Rising focus on decentralized diagnostics 29
5.2.1.3 Growing demand for CLIA-waived molecular POC tests 30
5.2.2 RESTRAINTS 30
5.2.2.1 Inadequate reimbursements 30
5.2.2.2 Stringent and time-consuming regulatory policies significantly increase the product launch cycle 31
5.2.3 OPPORTUNITIES 31
5.2.3.1 Growing R&D activities in molecular diagnostic testing 31
5.2.3.2 Increasing penetration of POC molecular diagnostic tests in China, India, and Brazil 32
6 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 33
6.1 INTRODUCTION 34
6.1.1 RESPIRATORY DISEASES 34
6.1.2 SEXUALLY TRANSMITTED DISEASES 35
6.1.3 HOSPITAL-ACQUIRED INFECTIONS 36
6.1.4 ONCOLOGY 37
6.1.5 HEPATITIS 38
6.1.6 OTHER APPLICATIONS 40
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 41
7.1 INTRODUCTION 42
7.2 RT-PCR 42
7.3 INAAT 43
7.4 OTHER TECHNOLOGIES 45
8 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE 46
8.1 INTRODUCTION 47
8.2 ASSAYS & KITS 47
8.3 INSTRUMENTS/ANALYZERS 49
8.4 SOFTWARE & SERVICES 50
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 51
9.1 INTRODUCTION 52
9.2 PHYSICIAN OFFICES 52
9.3 HOSPITAL EMERGENCY DEPARTMENTS & INTENSIVE CARE UNITS 53
9.4 RESEARCH INSTITUTES 54
9.5 OTHER END USERS 55
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 57
10.1 INTRODUCTION 58
10.2 NORTH AMERICA 59
10.2.1 US 62
10.2.2 CANADA 63
10.3 EUROPE 66
10.4 ASIA PACIFIC 68
10.5 ROW 72
11 COMPETITIVE LANDSCAPE 74
11.1 MARKET OVERVIEW 74
11.2 MARKET RANKING ANALYSIS, 2017 74
11.3 COMPETITIVE SITUATION AND TRENDS 75
11.3.1 PRODUCT LAUNCHES AND APPROVALS 75
11.3.2 ACQUISITIONS 75
11.3.3 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS 76
11.3.4 EXPANSIONS 76
12 COMPANY PROFILE 77
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ABBOTT LABORATORIES 77
12.2 DANAHER CORPORATION 79
12.3 BIOMÉRIEUX SA 81
12.4 ROCHE DIAGNOSTICS 83
12.5 QUIDEL 85
12.6 MERIDIAN BIOSCIENCE 87
12.7 MESA BIOTECH 89
12.8 GENEPOC 90
12.9 DXNA 91
12.10 ATLAS GENETICS 92
12.11 SPARTAN BIOSCIENCE 93
12.12 BIOCARTIS 94

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 97
13.1 DISCUSSION GUIDE 97
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 100
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 102
13.4 AVAILABLE CUSTOMIZATIONS 104
13.5 RELATED REPORTS 105
13.6 AUTHOR DETAILS 106

LIST OF TABLES

TABLE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 34
TABLE 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016–2023 (USD MILLION) 35
TABLE 3 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2016–2023 (USD MILLION) 35
TABLE 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2016–2023 (USD MILLION) 36
TABLE 5 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2016–2023 (USD MILLION) 36
TABLE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY REGION, 2016–2023 (USD MILLION) 37
TABLE 7 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY COUNTRY, 2016–2023 (USD MILLION) 37
TABLE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY,
BY REGION, 2016–2023 (USD MILLION) 38
TABLE 9 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION) 38
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,
BY REGION, 2016–2023 (USD MILLION) 39
TABLE 11 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2016–2023 (USD MILLION) 39
TABLE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2016–2023 (USD MILLION) 40
TABLE 13 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 40
TABLE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 42
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY REGION, 2016–2023 (USD MILLION) 42
TABLE 16 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2016–2023 (USD MILLION) 43
TABLE 17 PRODUCT APPROVALS IN THE LAST THREE YEARS 43
TABLE 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY REGION, 2016–2023 (USD MILLION) 44
TABLE 19 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2016–2023 (USD MILLION) 44
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2023 (USD MILLION) 45
TABLE 21 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2023 (USD MILLION) 45
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 47
TABLE 23 POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION,
2016–2023 (USD MILLION) 48
TABLE 24 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 48
TABLE 25 POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY REGION, 2016–2023 (USD MILLION) 49
TABLE 26 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2016–2023 (USD MILLION) 49
TABLE 27 POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY REGION, 2016–2023 (USD MILLION) 50
TABLE 28 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2016–2023 (USD MILLION) 50
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2016–2023 (USD MILLION) 52
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES,
BY REGION, 2016–2023 (USD MILLION) 52
TABLE 31 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2016–2023 (USD MILLION) 53
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY REGION, 2016–2023 (USD MILLION) 53
TABLE 33 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY COUNTRY, 2016–2023 (USD MILLION) 54
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION) 54
TABLE 35 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION) 55
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,
BY REGION, 2016–2023 (USD MILLION) 55
TABLE 37 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2023 (USD MILLION) 56
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2016–2023 (USD MILLION) 58
TABLE 39 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 60
TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 60
TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 60
TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2016–2023 (USD MILLION) 61
TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2016–2023 (USD MILLION) 61
TABLE 44 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 62
TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 62
TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2016–2023 (USD MILLION) 63
TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 63
TABLE 48 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 64
TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 64
TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2016–2023 (USD MILLION) 65
TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2016–2023 (USD MILLION) 65
TABLE 52 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 66
TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 66
TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2016–2023 (USD MILLION) 67
TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2016–2023 (USD MILLION) 67
TABLE 56 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2018–2023 (USD MILLION) 70
TABLE 57 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 70
TABLE 58 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2016–2023 (USD MILLION) 71
TABLE 59 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2016–2023 (USD MILLION) 71
TABLE 60 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2018–2023 (USD MILLION) 72
TABLE 61 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 72
TABLE 62 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2016–2023 (USD MILLION) 73
TABLE 63 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2016–2023 (USD MILLION) 73
TABLE 64 RANK OF COMPANIES IN THE GLOBAL MOLECULAR POC DIAGNOSTIC
MARKET, 2017 74
TABLE 65 PRODUCT LAUNCHES, 2015-2018 75
TABLE 66 ACQUISITIONS, 2015-2018 75
TABLE 67 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS, 2015 & 2018 76
TABLE 68 EXPANSIONS, 2015 TO 2018 76

 


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 14
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 16
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 19
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 19
FIGURE 5 DATA TRIANGULATION 20
FIGURE 6 POC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2018 VS. 2023 22
FIGURE 7 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018 VS. 2023 23
FIGURE 8 POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018 VS. 2023 23
FIGURE 9 NORTH AMERICA TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET
IN 2018 24
FIGURE 10 INCREASING WORLDWIDE PREVALENCE OF INFECTIOUS DISEASES, A KEY DRIVER FOR THE GROWTH OF THE POC MOLECULAR DIAGNOSTICS MARKET 25
FIGURE 11 ASSAYS & KITS TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN ASIA PACIFIC IN 2017 26
FIGURE 12 RESPIRATORY DISEASES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 27
FIGURE 13 PHYSICIAN OFFICES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 27
FIGURE 14 POC MOLECULAR DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS, & OPPORTUNITIES 28
FIGURE 15 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 59
FIGURE 16 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 69
FIGURE 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT ( 2017) 77
FIGURE 18 DANAHER CORPORATION: COMPANY SNAPSHOT (2017) 79
FIGURE 19 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2017) 81
FIGURE 20 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017) 83
FIGURE 21 QUIDEL: COMPANY SNAPSHOT (2016) 85
FIGURE 22 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017) 87
FIGURE 23 BIOCARTIS: COMPANY SNAPSHOT (2017) 94



【レポートのキーワード】

PoC分子診断

★調査レポート[PoC分子診断の世界市場予測（～2023年）] ( Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023 / MD6292) 販売に関する免責事項
[PoC分子診断の世界市場予測（～2023年）] ( Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023 / MD6292) についてEメールでお問い合わせ

※関連データはありません。


◆H&Iグローバルリサーチ株式会社のお客様（例）◆